Press Room

News / May 11, 2017

Bioconnect Seminar at the Hovione Cork Site

The Hovione site welcomed close to 50 people from the Irish Pharma, Biotech and University sectors for a combined seminar with Bioconnect Ireland on the theme of Tech Transfer in the pharmaceutical industry.

Bioconnect Seminar at the Hovione Cork Site | Hovione

Paul Downing, General Manager of Hovione Cork, gave the opening address and introduced Jim Ryan CEO of Bioconnect Ireland who chaired the meeting. First on the Podium was Brian Harrison who previously held many management positions in Bristol-Myers-Squibb and now Managing Director of his own start-up outfit. He gave an overview of the Tech transfer process and the importance of aligning the same mindset on both the receiving site and transfer site. This followed by two of our own guest speakers Rui Loureiro and Márcio Temtem both of whom gave complementary presentations on techniques to overcome solubility issues and effective use of modeling to have a robust process for scale-up. The presentations were varied in their themes from Biotech start-ups to mainstream pharma distribution companies. An interesting QA session was followed by a group photo in front of Building 10. Paul Dunne European, Business Development Manager, presided over the wrap up before the site tour. The evening concluded with a networking and drinks reception in the China room.

Bioconnect Seminar at the Cork Site | Hovione

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025